Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 6, 2010 - Issue 8
Submit an article Journal homepage
434
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluations

Entacapone

Thomas Müller St. Joseph Hospital Berlin-Weißensee, Department of Neurology, Gartenstr. 1, 13088 Berlin, Germany +49 30 92790223; +49 30 92790703; [email protected]; Ruhr University of Bochum, 44789 Bochum, Germany
, MD
Pages 983-993 | Published online: 24 Jun 2010

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Thomas Müller. (2021) Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence. Journal of Experimental Pharmacology 13, pages 397-408.
Read now
Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Sohaila AlShimemeri, Susan H Fox & Naomi P Visanji. (2020) Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update. Expert Opinion on Emerging Drugs 25:2, pages 131-144.
Read now
Cornelis J Van der Schyf. (2015) Rational drug discovery design approaches for treating Parkinson’s disease. Expert Opinion on Drug Discovery 10:7, pages 713-741.
Read now

Articles from other publishers (15)

Angelo Antonini, Valentina D’Onofrio & Andrea Guerra. (2023) Current and novel infusion therapies for patients with Parkinson's disease. Journal of Neural Transmission 130:11, pages 1349-1358.
Crossref
Destany K. Kwon, Mohit Kwatra, Jing Wang & Han Seok Ko. (2022) Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies. Cells 11:23, pages 3736.
Crossref
Zhongqiong Wang, Chengyi Wang, Bing He, Wei Zhang, Li Liu, Mingming Deng, Muhan Lü, Xiaoyi Qi & Sicheng Liang. (2022) Determination of Daphnetin and its 8-O-Methylated Metabolite in Rat Plasma by UFLC-MS/MS: Application to a Pharmacokinetic Study. Chromatographia 85:4, pages 333-341.
Crossref
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 3309 3326 .
Trisha Bhatt, Bhoomika M. Patel & Mayur M. Patel. 2021. Drug Delivery Devices and Therapeutic Systems. Drug Delivery Devices and Therapeutic Systems 491 513 .
Dae Young Yoo, Hyo Young Jung, Woosuk Kim, Kyu Ri Hahn, Hyun Jung Kwon, Sung Min Nam, Jin Young Chung, Yeo Sung Yoon, Dae Won Kim & In Koo Hwang. (2020) Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking. Cells 9:12, pages 2712.
Crossref
Dirk Woitalla, Rejko Krüger, Stefan Lorenzl, Thomas Müller, Guenther Oelwein, Alexander Storch, Martin Wolz & Ullrich Wüllner. (2020) Grundlagen und Stellenwert der COMT- und MAO-B-Inhibitoren in der Therapie des idiopathischen Parkinson-Syndroms. Fortschritte der Neurologie · Psychiatrie 88:09, pages 620-633.
Crossref
Thomas Müller. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 18 .
Kentaro Ono, Chi T. Viet, Yi Ye, Dongmin Dang, Suzuro Hitomi, Takashi Toyono, Kiyotoshi Inenaga, John C. Dolan & Brian L. Schmidt. (2017) Cutaneous pigmentation modulates skin sensitivity via tyrosinase-dependent dopaminergic signalling. Scientific Reports 7:1.
Crossref
L.P. Kotra & J. Park. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 439 473 .
Thomas Müller. (2015) Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease. Drugs 75:2, pages 157-174.
Crossref
Li-Sheng Li. (2015) Effect of entacapone on colon motility and ion transport in a rat model of Parkinson’s disease. World Journal of Gastroenterology 21:12, pages 3509.
Crossref
Thomas Müller. (2012) Drug therapy in patients with Parkinson’s disease. Translational Neurodegeneration 1:1.
Crossref
. 2012. Pharmacokinetics and Metabolism in Drug Design. Pharmacokinetics and Metabolism in Drug Design 111 158 .
Lawrence ElmerRobert A Hauser. (2011) Strategies for Parkinson’s disease care: prevention and management of motor fluctuations. Neurodegenerative Disease Management 1:5, pages 415-430.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.